Interview Highlights Thompson’s Entrepreneurial Vision and Kraig Labs’ Mission to Bring Spider Silk to Commercial Scale

ANN ARBOR, Mich., July 10, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that CEO and Founder, Kim Thompson, is featured in Authority Magazine’s “Meet the Disruptors” series, a widely read publication on the Medium platform (www.Medium.com) profiling business leaders who are reshaping their industries. The interview explores Thompson’s entrepreneurial background, his philosophy on innovation, and Kraig Labs’ mission to bring recombinant spider silk to commercial-scale production.

Authority Magazine’s “Meet the Disruptors” series reaches a broad audience of entrepreneurs, investors, and business leaders. The feature positions Thompson alongside industry innovators who are challenging convention and building something fundamentally new.

In the interview, Thompson described what makes Kraig Labs’ work genuinely disruptive and why the material at its center truly matters.

“Spider silk is a remarkable material that is among the strongest and toughest natural materials,” Thompson told Authority Magazine. “Spider silk has the potential to make significant impacts in textile markets and provide mankind with advanced, nature-produced materials, which have unique properties including strength, toughness, and beauty.”

Thompson also offered a candid look at what’s next for the Company and signaled that recombinant spider silk is only the beginning.

“At Kraig Labs, we are currently scaling up recombinant spider silk production to commercial quantities,” stated Thompson. “Next on our near-term agenda is the introduction of new spider silk and other biological materials never seen in the marketplace, with enhanced and, in some cases, unusual properties.”

The interview also drew on Thompson’s broader philosophy of innovation, which has defined his approach from his earliest business ventures to the founding of Kraig Labs. Asked to share the principles that have driven his success, Thompson identified independent thinking as essential.

“I learned to rely on my own instincts while still engaging with experts for criticism and independent insight,” he said. “Often, the experts know what they are doing, but it is important to challenge their assumptions, especially when you are doing something new.”

That instinct proved decisive at a pivotal moment in the Company’s history. Thompson described studying Nexia Biotechnologies. At the time, the foremost scientific team working on spider silk. Thompson recognized a fundamental flaw in their approach before it became public.

“As I studied their biotechnology, it became obvious to me that they had completely missed the mark and that the technology would never work as planned,” Thompson said. “Two years later, they hit the wall I had predicted. They collapsed, and I bought the rights to use the gene sequences.”

Those gene sequences became the foundation of Kraig Biocraft Laboratories and its proprietary spider silk technology platform, the same platform now driving some of the largest recombinant spider silk production cycles ever recorded.

Kraig Labs believes this growing recognition from influential media platforms reflects the Company’s rising profile among entrepreneurs, investors, and innovators, and reinforces the broader narrative of a company that continues to push the limits of science, doing what others said couldn’t be done.

The full interview is available on Authority Magazine’s website at https://medium.com/authority-magazine/meet-the-disruptors-kim-thompson-of-kraig-biocraft-laboratories-on-the-five-things-you-need-to-baeeb6ff2590  

---

The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Company’s Founder Details Production Growth, Industry Transformation Strategy, and Expanding Commercial Opportunities for Recombinant Spider Silk

ANN ARBOR, Mich., June 15, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that Founder and Chief Executive Officer Kim Thompson was recently featured in an extensive interview with Pulse 2.0, where he discussed the Company’s technological leadership, commercial production progress, expanding market opportunities, and long-term vision for transforming the global advanced materials industry.

The interview comes as Kraig Labs continues to execute on its strategy of scaling commercial production of recombinant spider silk through its proprietary genetically engineered silkworm platform, an approach the Company believes provides significant advantages over alternative spider silk production methods.

In the interview, Thompson highlighted one of the Company’s core differentiators: its ability to leverage an existing global silk production infrastructure rather than requiring the creation of an entirely new manufacturing ecosystem.

“From the beginning, we believed that if spider silk was going to become a commercial material, it needed to fit into existing supply chains and manufacturing systems. That belief shaped our strategy from day one. We believe it is a major reason why we are now seeing success at commercial scale,” Thompson stated.

He further emphasized the scale of the opportunity available through Kraig’s production model.

“We leverage an existing global textile infrastructure already producing more than 150,000 metric tons of silk,” Thompson explained. “We are not building an entirely new industry. We are transforming one that already works at an extraordinary scale. That is a profound competitive advantage.”

The interview explored the scientific and manufacturing challenges that have historically limited commercial spider silk production and detailed why Kraig Labs believes its platform is uniquely positioned to overcome those barriers.

Unlike fermentation-based approaches that produce spider silk proteins requiring artificial processing into fibers, Kraig Labs’ genetically engineered silkworms naturally spin recombinant spider silk fibers through biological processes refined over millions of years of evolution.

“Our silkworms spin naturally, resulting in fiber quality that fermentation simply cannot match. Our manufacturing process is fully compatible with the existing global silk and textile industry,” said Thompson.

The discussion also highlighted recent technological achievements that continue expanding the Company’s intellectual property portfolio and advanced materials platform.

“Our most recent work, which I genuinely believe is the most ambitious application of genetic engineering to materials science in world history, is pushing the boundaries of what spider silk proteins can be,” Thompson stated.

He further noted that the Company has established a world record for the largest gene insert in silkworms and has successfully engineered recombinant versions of Darwin Bark Spider silk, one of the toughest biological materials ever measured, while also opening the door to entirely new classes of biomaterials.

Operational execution was another major focus of the interview. Thompson discussed how advances such as the BAM-1 hybrid and BAM-1 Alpha production systems, combined with the Company’s strategic expansion into Southeast Asia, have helped establish the foundation for commercial-scale production.

“Moving our rearing centers gave us access to a mature supply chain, skilled workers, and facilities critical to rapidly scale production. All of that builds the vertical integration that enables sustained monthly metric-ton-level production,” Thompson continued.

The interview also underscored the growing commercial opportunity for recombinant spider silk as brands, manufacturers, and consumers increasingly seek materials that combine sustainability with high-performance characteristics.

“Recombinant spider silk changes that equation entirely. It is a nature-derived, protein-based fiber that has the potential to outperform alternatives by blending strength, toughness, and elasticity. You don’t have to choose between sustainability and performance. You get both. That is an extremely compelling value proposition in today’s market,” Thompson said.

Kraig Labs believes this combination of performance and sustainability positions recombinant spider silk to address opportunities across premium apparel, performance textiles, luxury fashion, technical textiles, composites, defense applications, and future markets still emerging.

Looking ahead, Thompson outlined a vision centered on scaling production, expanding commercial adoption, and establishing Kraig Labs as the leading supplier of recombinant spider silk materials globally.

“Success, to me, looks like sustained monthly metric-ton-level production. Our silk flowing into the commercial supply chains for textiles, performance apparel, and luxury fashion,” Thompson said.

“The target is not just volume. It’s reliability, repeatability, and scalability for real commercial production. The world’s first. That’s what we’re delivering.”

The interview also reflected on the skepticism that has surrounded commercial spider silk production for decades and the Company’s progress in demonstrating that large-scale production is achievable.

“When we started, many people questioned whether commercial spider silk production was even possible. Today, we are operating at production scales that very few thought achievable just two years ago. That progress gives me tremendous confidence in where this company is headed and in the long-term future of this technology,” Thompson concluded.

The full interview is available on Pulse 2.0’s website, at https://pulse2.com/kraig-biocraft-laboratories-profile-kim-thompson-interview/?brid=YWdncwHtz6bJcFj_cp3jt9njafd9

---

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Company Continues Delivering on Aggressive 2026 Expansion Strategy as Production Scale Reaches New Heights

ANN ARBOR, Mich., June 9, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the successful completion of its latest production cycle (harvest from May 15 to June 4). This is the largest in the Company’s history, producing nearly 2.5 metric tons of recombinant spider silk cocoons. The milestone represents the Company’s most significant single-cycle output to date and delivers another powerful proof point in Kraig Labs’ aggressive 2026 expansion strategy.

With each successive production cycle, Kraig Labs has demonstrated a systematic ability to expand output at scale. The May/June cycle continues that trajectory with another substantial and measurable leap forward.

From the outset of 2026, the Company outlined an ambitious roadmap centered on rapid expansion and accelerating output by bringing new production capacity online. This latest production cycle is a continuing validation of a production system designed for success from the ground up.

“We said 2026 would be a year of aggressive expansion and accelerating production, and our team continues to execute on that commitment,” said Kim Thompson, CEO and Founder of Kraig Labs. “Nearly 2.5 metric tons from a single production cycle is a first for industry and a world record. Each production cycle is getting larger. Our systems are performing. Our expansion model for recombinant spider silk production is delivering results.”

The Company’s production expansion program has advanced on multiple fronts simultaneously, rapidly increasing capacity by bringing new facilities online. These compounding investments have enabled Kraig Labs to dramatically increase output while maintaining the disciplined, stepwise approach that management believes is essential for sustainable commercial-scale growth.

“We made strategic investments in the right genetics, the right facilities, and the right people,” Thompson continued. “Today, those investments are translating into larger production cycles, higher output, and sustained momentum.”

With processing activities now underway for the recently harvested recombinant spider silk, the Company remains squarely focused on maintaining its expansion pace and driving further increases in production capacity.

Kraig Labs believes these repeated, record-setting production milestones are decisively strengthening its position as the global leader in spider silk technologies.

---

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Company Reports Record Early Production Results, Exceeding Yield Targets by 20%

ANN ARBOR, Mich., May 26, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that cocoon collection has begun for its current recombinant spider silk production cycle. Early production results show production yields exceeding targets by 20%.

These higher-than-expected yields are resulting in a significant increase in finished silk output. If these early results hold throughout the production run, Kraig Labs will produce the largest run of recombinant spider silk to date.

“This is another exciting moment for the Company, our production team, and shareholders,” said Kim Thompson, CEO and Founder of Kraig Labs. “At the beginning of this year, we laid out an aggressive production roadmap with a series of ambitious milestones. To date, we have successfully hit every major milestone on schedule and on budget. The yields we are seeing from this recombinant spider silk production run are exceeding our internal forecasts and expectations.”

The Company stated that the current production cycle remains underway, with cocoon collection continuing over the coming weeks as additional production centers complete their collections. Based on the initial results and current field performance, management expects this production cycle to exceed the output of the previous record-setting batch.

“These early yields are extremely encouraging,” Thompson added. “Not only are we seeing production volumes ahead of target, but we are also seeing the operational consistency and execution needed to sustain large-scale spider silk production. The systems, facilities, and production partnerships we have built are all performing exactly as designed.”

Kraig Labs also confirmed that preparations are already underway for the next major production expansion cycle scheduled for June/July. Management expects that batch will exceed the size of this current run, continuing the rapid acceleration of recombinant spider silk production.

“Our team has spent years building the foundation for this moment,” Thompson said. “What we are seeing now is the result of disciplined planning, proven production models, strong genetics, and operational execution coming together at exactly the right time.”

The Company indicated that additional production updates are expected in the coming weeks.

---

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., May 20, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced additional details regarding the significant advantages of the Company’s newly developed immortalized silk gland cell platform.

The Company recently announced the successful isolation and immortalization of silkworm posterior silk gland cells, a breakthrough designed to support next-generation recombinant protein manufacturing and advanced biomaterial production.

Kraig Labs’ technology differs significantly from conventional baculovirus insect cell expression systems commonly used throughout the biotechnology industry.

Traditional insect cell systems require cells to be infected and driven to produce a target protein until the cells are ultimately killed and destroyed to extract the protein. Once harvested, the process must begin again with a new batch of cells.

Kraig Labs’ system is designed around a fundamentally different approach.

Using natural exocytosis-based protein secretion pathway, the Company’s immortalized silk gland cells continuously produce and release target proteins into the surrounding culture media. Because the proteins are secreted naturally rather than retained inside the cells, they can potentially be harvested and purified more efficiently and repeatedly without disrupting or destroying the producer cells.

The Company believes this approach may offer several important manufacturing advantages.

Because the cells remain alive after protein collection, they can continue producing target proteins over extended production cycles. At the same time, collecting proteins directly from the surrounding media should reduce the need for more complex processing and purification steps typically associated with conventional intracellular production systems.

Together, these advantages may support faster production timelines, lower operating costs, improved scalability, and greater overall manufacturing efficiency.

“Our platform is designed to work with the silkworm’s natural biological systems,” said Kim Thompson, Founder and CEO of Kraig Labs. “Rather than destroying cells during protein recovery, our approach allows the cells to remain productive while continuously releasing target proteins into the surrounding media. We believe this technology could represent an important advancement in recombinant protein manufacturing.”

Kraig Labs believes its immortalized silk gland cell culture platform may represent an important evolution far beyond traditional systems by combining continuous protein production with natural protein secretion and simplified downstream recovery.

---

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., May 18, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced a biotechnology breakthrough with the successful creation of an immortalized silk gland cell line. The Company believes this technology could form the foundation for a next-generation biotechnology platform with potential applications in biopharmaceutical manufacturing, therapeutic peptides, biologically active proteins, and advanced biomaterials.

This breakthrough significantly expands the potential commercial reach of the Company’s core technologies beyond recombinant spider silk fibers and textiles. The Company’s research division continues to advance next-generation biotechnology platforms designed to unlock new commercial opportunities across multiple biotech sectors.

“This scientific achievement expands the Company’s technological reach and opens the potential for entirely new markets,” said Kim Thompson, Founder and CEO of Kraig Labs. “While our research team is expanding our portfolio and creating exciting new opportunities, management remains focused on the ongoing expansion of recombinant spider silk production and commercialization.”

As part of the scientific advancement announced today, the Company’s research team successfully isolated and established immortalized silk gland cells that demonstrate strong proliferative capacity, stable serial passaging, and robust long-term viability in vitro. Early testing has shown exceptionally strong recombinant protein expression and production capabilities, positioning the platform as a promising candidate for scalable industrial bioprocessing and recombinant protein manufacturing.

“The potential applications for this technology are extraordinarily broad,” said Xiaoli Zhang, Kraig Labs’ Chief Scientist. “We believe these immortalized silk gland cells could become the basis for a highly versatile biotechnology platform capable of supporting future work in therapeutics, vaccines, recombinant proteins, and next-generation biomaterials.”

The immortalized cell line has also demonstrated promising adaptability toward suspension culture systems, a critical requirement for large-scale industrial manufacturing and modern bioprocessing. This capability could allow the platform to integrate with conventional bioprocessing infrastructure and support more efficient, scalable, and cost-effective production systems.

“This achievement represents a major scientific milestone for our research team and highlights the depth of the biotechnology platform we have built,” added Thompson. “As we aggressively expand spider silk production operations, we are also investing in next-generation technologies that could open entirely new commercial markets for the Company. We believe this development has the potential to create opportunities in biotechnology sectors far beyond textiles. It is another example of our team’s leadership in this area of advanced biotechnology.”

The Company believes the unique biology of silkworm silk gland cells may provide important advantages for the production of specialized proteins and other biologically active compounds.

“This work demonstrates that Kraig Labs technological lead is not limited to advanced fibers and recombinant spider silks,” continued Thompson. “We are building broader biotechnology platforms centered on advanced genetic engineering, scalable biological manufacturing, and recombinant protein technologies.”

---

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., May 11, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the successful commissioning of another recombinant spider silk production rearing center. The new facility is already in operation as part of the Company’s aggressive and strategic production expansion program.

The newly commissioned facility was brought online in less than 30 days. It is now supporting the Company’s April/May production cycle. Management expects this production cycle to set new records once again as Kraig Labs advances toward its goals for commercial-scale recombinant spider silk production.

The rapid deployment of this facility reflects the Company’s growing expertise in scaling production. Kraig Labs has standardized facility layouts, production workflows, staffing procedures, and operational systems. This approach allows the Company to quickly duplicate recombinant spider silk production capacity.

“This new rearing center is already expanding our production,” said Kim Thompson, CEO and Founder of Kraig Labs. “As we rapidly expand production, we are also increasing efficiency. Each new facility benefits from the experience gained from the previous production runs.”

The Company’s multi-facility production strategy is designed to increase both capacity and resiliency. By operating across multiple production centers, Kraig Labs creates operational redundancy and reduces concentration risk. The strategy also gives the Company greater flexibility as it rapidly scales toward commercial production targets.

According to the Company, the newest facility follows the same production architecture and operational framework already proven in prior facilities. This standardization allows new production centers to come online faster and more efficiently with each expansion cycle.

“This is exactly how we planned to scale this business,” continued Thompson. “We are no longer building one-off pilot operations to test system performance. We now have a system that has demonstrated the ability to produce recombinant spider silk at larger and larger scales. This new facility will play a central role in our production as we rapidly move to full commercial scale.”

The commissioning of this facility follows a series of recent production milestones. Earlier this year, the Company launched an aggressive scale-up initiative aimed at rapidly increasing recombinant spider silk output. Since then, Kraig Labs has expanded production capacity, deployed new production hybrids, increased cocoon processing throughput, and achieved consecutive record-setting production runs.

Management believes the April/May production cycle will represent another major step forward in the Company’s commercialization roadmap. Kraig Labs expects to continue deploying additional production capacity throughout 2026.

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Company Increases Production Capacity Again as it Advances toward Production Goals

ANN ARBOR, Mich., May 4, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has officially launched its next production cycle following the Company’s recent record-setting production run.

Earlier this month, the Company announced the successful production of nearly 1.8 metric tons of recombinant spider silk cocoons. 1.8 metric tons was the largest production run in the Company’s history. Today, Kraig Labs confirmed that its follow-on production cycle is underway. Consistent with the Company’s aggressive commercialization strategy, this cycle is expected to show a substantial increase over the previous cycle.

This next production expansion represents another major step in the Company’s carefully structured plan to rapidly scale output toward its long-term objective of producing more than 10 metric tons of recombinant spider silk cocoons in a single month.

“Our team continues to execute exactly as planned,” said Kim Thompson, Founder and CEO of Kraig Labs. “Each production cycle is delivering larger output, improved operational efficiency, and, with our quality control backstops working as designed, greater confidence in our ability to scale. We are systematically building toward our goal of exceeding 10 metric tons of production in a single month. Our team is hitting every mark as we scale output at a rapid pace.”

During senior management’s recent trip to the Company’s production operations in Southeast Asia, leadership worked directly with the production team to review current production infrastructure, staffing levels, and operational readiness to support this next phase of expansion.

That review included evaluating existing facilities, workforce requirements, and identifying additional opportunities to expand the Company’s operational footprint to support increasing production demands. The Company has already identified opportunities for additional facility expansion and expects to provide further updates as new facilities are brought online.

“Our recent operational review confirmed that our production team is prepared for this next level of scale,” added Thompson. “We continue to invest in the infrastructure, personnel, and production capacity required to meet the growing demand we anticipate for recombinant spider silk.”

The Company believes that expanding production capacity in parallel with downstream silk processing capabilities remains critical as it moves toward full commercialization of its recombinant spider silk technologies for technical textiles, luxury wear, performance apparel, and other high-performance material markets.

---

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., April 28, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced significant progress in the processing of its recently produced recombinant spider silk cocoons into reeled silk.

Earlier this month, Kraig Labs announced that it had successfully produced nearly 1.8 metric tons of recombinant spider silk cocoons, marking a historic milestone in the commercialization of spider silk. Today, the Company confirmed that the conversion of those cocoons into reeled silk fiber is now approximately 50% complete.

The silk currently being processed represents the largest volume of recombinant spider silk ever produced by Kraig Labs and is now moving through the next critical stage of commercialization. Once complete, this processing cycle will yield a substantial inventory of spider silk fiber ready to support ongoing product development initiatives and future commercial opportunities.

The accompanying image in this release highlights only a portion of the reeled silk already produced from this record-setting production run. As processing continues, the Company expects total silk output to increase significantly as the remaining cocoons are converted into reeled silk.

“This is exactly the kind of operational execution we have been working toward,” said Kim Thompson, Founder and CEO of Kraig Labs. “Producing nearly 1.8 metric tons of recombinant spider silk cocoons was a landmark achievement. Successfully converting that production into reeled silk is the next major step in transforming our spider silk technology into commercially available yarns and fabrics. The image shared today represents only a portion of what has already been processed, and we remain on pace to complete this work in line with our broader production strategy.”

This milestone represents another breakthrough in the Company’s strategy to establish the world’s first and only reliable, commercially scalable, and cost-effective supply chain for spider silk, nature’s super material.

---

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., April 20, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has begun processing nearly 1.8 metric tons of recombinant spider silk cocoons into finished reeled silk.

In early April, the Company announced that it had exceeded 1.3 metric tons of cocoon production in March, setting a new production record. Since that announcement, Kraig Labs is now confirming that it produced an additional half ton of cocoons (approximately) that were not included in the in the March report. This brings the Company’s total available cocoon inventory to nearly 1.8 metric tons. The attached image represents less than 4% of the total cocoon production.

Kraig Labs has now initiated the reeling process, converting this inventory into finished reeled silk. This work is currently underway at one of the Company’s production partners and is expected to be completed by the end of the month.

Upon completion of this processing phase, Kraig Labs expects to hold the largest inventory of recombinant spider silk in its history. To the Company’s knowledge, this volume also represents the largest single supply of recombinant spider silk ever to exist.

The finished reeled silk will shortly be available for processing, including twisting into yarns and integration into textile and technical material applications. Kraig Labs plans to make these materials available to targeted markets, including luxury fashion, performance textiles, and industrial applications.

Senior management is currently in Asia overseeing these operations. During this visit, leadership is working directly with production staff to monitor the reeling process, evaluate facility performance, and coordinate with supply chain partners. Management is also advancing the implementation of the Company’s aggressive scale-up strategy. This plan is designed to continue rapidly increasing production output in the months ahead.

“The execution we are seeing across our operations is tracking exactly as we expected,” said Kim Thompson, Founder and CEO of Kraig Labs. “That is a direct result of the considerable groundwork our team has completed over the last three years to put our production infrastructure in place and fine tune our processes in the field. What we are seeing now is preparation translating into consistent, scalable output.”

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com